Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyramid: Pyrotinib vs Pertuzumab in Neoadjuvant Treatment of HER2+ Breast Cancer
NCT04900311Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2021; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04900311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900311.